Erasca, Inc. (NasdaqGS: ERAS)
Health Care · Biotechnology · US
$17.76
+0.91% today · +1017.0% 1Y
Erasca, Inc. (NasdaqGS: ERAS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.21B and employs 103 people.
Over the last twelve months the share price has gained 1017.0%, trading between 1.33 and 24.28.
Tweenvest scores Erasca, Inc. across four factors: quality 28/100. Its strongest factor is quality.
ERAS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.21B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.97
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- $24.28
- 52-week low
- $1.33
- Avg volume (3M)
- —
- Shares outstanding
- 349.76M
- Employees
- 103
- Next earnings
- —
About Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
- ISIN
- US29479A1088
- Founded
- 2018
- Listed since
- Jul 16, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.